Monitoring Antimalarial Drug Efficacy

Ringwald, P.
April 2004
Clinical Infectious Diseases;4/15/2004, Vol. 38 Issue 8, p1192
Academic Journal
Presents letters to the editor on antimalarial drug efficacy, published in the April 15, 2004 issue of the journal "Clnical Infectious Diseases." Effects of the chemical compound sulfadoxine-pyrimethamine therapy; Results of clinical trials for drug resistance; Antimalarial drug efficacy in low transmission areas.


Related Articles

  • Screening of antimalarial drugs: An overview. Kalra, Bhupinder Singh; Chawla, S.; Gupta, P.; Valecha, N. // Indian Journal of Pharmacology;Feb2006, Vol. 38 Issue 1, p5 

    Efforts to discover and develop new antimalarial drugs have increased dramatically in recent years mainly because of resistance to existing antimalarial drugs. Selection of candidate drugs for clinical trials in man and the design of clinical protocols are based upon consideration of data from a...

  • Study confirms benefits of metronidazole gel tx. Guttman, Cheryl // Dermatology Times;Mar2005, Vol. 26 Issue 3, p58 

    The article cites a study which confirms benefits of metronidazole gel tx. Results of a large, nationwide, community-based phase 4 clinical trial reaffirm that metronidazole gel 0.75 percent (MetroGel, Galderma) safely and effectively treats rosacea while simultaneously improving quality of life...

  • New malaria combination cheaper and easier to take. Sibbald, Barbara // CMAJ: Canadian Medical Association Journal;6/7/2005, Vol. 172 Issue 12, p1545 

    Deals with the antimalaria formulation developed by the Drugs for Neglected Disease initiative to be available in 2006. Advantage of the drug over other antimalarials; Organizations that support the drug; Drug company to manufacture the antimalaria.

  • Antimalarial treatment with artemisinin combination therapy in Africa. Malenga, Grace; Palmer, Ayo; Staedke, Sarah; Kazadi, Walter; Mutabingwa, Thonest; Ansah, Evelyn; Barnes, Karen I.; Whitty, Christopher J. M. // BMJ: British Medical Journal (International Edition);10/1/2005, Vol. 331 Issue 7519, p706 

    Presents an editorial regarding antimalarial treatment with artemisinin combination therapy in Africa. Increase of drug resistant malaria across Africa; Report that combination therapies are now seen to be the best solution for treating malaria; Effectiveness of artemisinin based drug...

  • Antimalarial drug discovery: efficacy models for compound screening. Fidock, David A.; Rosenthal, Philip I.; Croft, Simon L.; Brun, Reto; Nwaka, Solomon // Nature Reviews Drug Discovery;Jun2004, Vol. 3 Issue 6, p509 

    Increased efforts in antimalarial drug discovery are urgently needed. The goal must be to develop safe and affordable new drugs to counter the spread of malaria parasites that are resistant to existing agents. Drug efficacy, pharmacology and toxicity are important parameters in the selection of...

  • The Role of Antimalarials in the Exacerbation of Psoriasis: A Systematic Review. Herman, Sari M.; Shin, Michael H.; Holbrook, Anne; Rosenthal, Donald // American Journal of Clinical Dermatology;2006, Vol. 7 Issue 4, p249 

    OBJECTIVE: To critically review the body of literature that refutes or supports the role of antimalarials in the exacerbation of psoriasis. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were reviewed to identify English-language publications from...

  • Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. Plowe, Christopher V.; Kublin, James G.; Dzinjalamala, Fraction K.; Kamwendo, Deborah S.; Mukadam, Rabia A. G.; Chimpeni, Phillips; Molyneux, Malcolm E.; Taylor, Terrie E. // BMJ: British Medical Journal (International Edition);3/6/2004, Vol. 328 Issue 7439, p545 

    Objective: To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line treatment in that country in 1993. Design: Prospective open label drug efficacy study. Setting:...

  • Clioquinol -- A Novel Copper-Dependent and Independent Proteasome Inhibitor. Schimmer, A. D. // Current Cancer Drug Targets;Mar2011, Vol. 11 Issue 3, p325 

    No abstract available.

  • Cefminox versus Metronidazole plus Gentamicin in intra-abdominal infections: A Prospective Randomized Controlled Clinical Trial. Torres, A. J.; Valladares, L. Díez; Jover, J. M.; Sánchez -Pernaute, A.; Frías, J.; Carcas, A. J.; Coronel, P.; Ródenas, E.; Pérez-Balcabao, I.; Fernández-Roblas, R.; Moreno, M.; Balibrea, J. L. // Infection;Oct2000, Vol. 28 Issue 5, p318 

    Background: The aim of this prospective study was to compare the safety and efficacy of a new cephamycin, cefminox 2 g/12 h, to those of the usual regimen combining metronidazole 500 mg/8 h and gentamicin 80 mg/8 h (M+G). Patients and Methods: 160 patients with clinically proven intra-abdominal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics